Rheumatoid Arthritis Long Flashcards
RA - Extra-articular Features
Skin - Raynaud’s, skin ulcers
Eyes - dry eyes, scleritis, episcleritis, scleromalacia perforans
sore throat, hoarseness, or neck pain - cervical spine
lungs - interstitial fibrosis, pleural effusion, pleuritis
heart - pericarditis, valve disease
neurology - peripheral neuropathy, mononeuritis multiplex, cord compression, entrapment neuropathy
hematologic
vasculitis
RA - signs of activity
Number of joints with active synovitis
severity and duration of morning stiffness
functional activity
symptoms of systemic illness
Methotrexate - Drug Complications
hepatic toxicity
lung toxicity (fibrosis)
marrow toxicity
rash
- worse on drinking alcohol
- folic acid to reduce complications
NOT FOR PATIENTS WITH G6PD
Sulfasalazine - Drug Complications
rash nausea hematological abnormalities abnormal liver function test reversible oligospermia
Penicillamine - Drug complications
nephrotic syndrome thrombocytopenia mouth ulcers SLE polymyositis myasthenia gravis Goodpasteur's syndrome
Components of Felty’s Syndrome
Rheumatoid arthritis
leucopenia
splenomegaly
non-healing ulcers
- Older patients with signs of Rheumatoid disease
Criteria for Diagnosis of RA
Morning stiffness >1 hour for >6 weeks Arthritis of 3 or more joint areas - soft tissue swelling of >6 weeks Arthritis of hand joints (NOT DIP) >6 weeks Symmetrical arthritis >6 weeks Rheumatoid nodules Serum RF X-ray changes consistent with RA
*4 out of 7 diagnostic
Xray Changes in RA
Soft tissue swelling
joint space narrowing
juxta-articular osteoporosis
joint erosions
RA - Risk Factors for Destructive Disease
High-titre RF or positive anti-CCP Constitutional symptoms Insidious onset Erosions early on xray Rheumatoid nodules early HLA DR4
RA - Tests for Monitoring Drug Complications
Full blood count
urine testing for proteinuria
LFTs (for MTX)
Ophthal review, visual fields (Plaquinil)
RA - Indications for Steroid Use
Vasculitic complications of RA
Severe progressive disease until other treatment becomes effective
chronic low-dose treatment